Compare Stocks: LKFT, ABVX, CYTK, and PRAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$94.13 -4.2%	$119.17	$69.81 ▼ $148.83	$8.59B	0.96	1.12 million shs	2.63 million shs
CYTK Cytokinetics	$65.81 -2.6%	$75.59	$47.22 ▼ $88.31	$8.41B	0.36	1.96 million shs	2.05 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$30.72 +1.8%	$28.24	$25.68 ▼ $37.78	$1.99B	0.28	271,003 shs	635,291 shs
PRAX Praxis Precision Medicines	$282.12 -6.2%	$337.62	$46.99 ▼ $392.70	$8.39B	2.76	350,754 shs	1.01 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-4.99%	-7.85%	-14.49%	+6.25%	+19.56%
CYTK Cytokinetics	0.00%	-2.48%	-12.04%	-16.76%	+40.08%
LKFT Lakefront Biotherapeutics American Depositary Shares	+2.03%	+8.13%	+4.83%	+4.07%	-10.39%
PRAX Praxis Precision Medicines	+0.60%	-3.91%	-20.01%	-2.68%	+522.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$94.13 -4.2%	$119.17	$69.81 ▼ $148.83	$8.59B	0.96	1.12 million shs	2.63 million shs
CYTK Cytokinetics	$65.81 -2.6%	$75.59	$47.22 ▼ $88.31	$8.41B	0.36	1.96 million shs	2.05 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$30.72 +1.8%	$28.24	$25.68 ▼ $37.78	$1.99B	0.28	271,003 shs	635,291 shs
PRAX Praxis Precision Medicines	$282.12 -6.2%	$337.62	$46.99 ▼ $392.70	$8.39B	2.76	350,754 shs	1.01 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-4.99%	-7.85%	-14.49%	+6.25%	+19.56%
CYTK Cytokinetics	0.00%	-2.48%	-12.04%	-16.76%	+40.08%
LKFT Lakefront Biotherapeutics American Depositary Shares	+2.03%	+8.13%	+4.83%	+4.07%	-10.39%
PRAX Praxis Precision Medicines	+0.60%	-3.91%	-20.01%	-2.68%	+522.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$156.69	66.46% Upside
CYTK Cytokinetics	2.85	Moderate Buy	$103.37	57.07% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.56	Moderate Buy	$37.00	20.44% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$612.42	117.08% Upside

Current Analyst Ratings Breakdown

Latest LKFT, ABVX, CYTK, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform	$26.00 ➝ $45.00
9/22/2026	ABVX Abivax	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$155.00 ➝ $151.00
9/22/2026	ABVX Abivax	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$140.00 ➝ $118.00
9/22/2026	ABVX Abivax	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$148.00
9/16/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/11/2026	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$155.00
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/1/2026	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight ➝ Buy
8/31/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
CYTK Cytokinetics	$88.04M	93.01	N/A	N/A	($5.39) per share	-12.21
LKFT Lakefront Biotherapeutics American Depositary Shares	$990.57M	2.04	$0.74 per share	41.58	$47.57 per share	0.65
PRAX Praxis Precision Medicines	$8.55M	921.26	N/A	N/A	$34.85 per share	8.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-91.69%	-71.96%	N/A
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)

Latest LKFT, ABVX, CYTK, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	-$1.71	-$0.7930	-$1.68	$0.80 million	$1.37 million
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	5.97	8.25
CYTK Cytokinetics	N/A	6.66	6.66
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
CYTK Cytokinetics	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
CYTK Cytokinetics	2.60%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	69	87.35 million	N/A	Not Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable

LKFT, ABVX, CYTK, and PRAX Headlines

Recent News About These Companies

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts

September 21 at 2:28 AM | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 21 at 2:28 AM | marketbeat.com

Praxis Precision Medicines Inc (PRAX)

September 19, 2026 | in.investing.com

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

September 12, 2026 | seekingalpha.com

8,060 Shares in Praxis Precision Medicines, Inc. $PRAX Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

September 11, 2026 | marketbeat.com

California State Teachers Retirement System Sells 874 Shares of Praxis Precision Medicines, Inc. $PRAX

September 11, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Bought Rep. Gilbert Ray Cisneros, Jr.

September 8, 2026 | marketbeat.com

Readystate Asset Management LP Takes $3.53 Million Position in Praxis Precision Medicines, Inc. $PRAX

September 7, 2026 | marketbeat.com

Seven Fleet Capital Management LP Acquires Shares of 7,540 Praxis Precision Medicines, Inc. $PRAX

September 5, 2026 | marketbeat.com

PRAX stock reacts to new Nasdaq inducement grants

September 4, 2026 | ad-hoc-news.deA

Wellington Management Group LLP Sells 48,483 Shares of Praxis Precision Medicines, Inc. $PRAX

September 4, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Praxis Precision Medicines, Inc. $PRAX is Velan Capital Investment Management LP's Largest Position

September 2, 2026 | marketbeat.com

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

August 31, 2026 | barrons.com

Bank of New York Mellon Corp Makes New $28.58 Million Investment in Praxis Precision Medicines, Inc. $PRAX

August 30, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Buy" from Brokerages

August 27, 2026 | marketbeat.com

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

August 17, 2026 | finance.yahoo.com

RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

August 11, 2026 | theglobeandmail.com

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

August 11, 2026 | zacks.com

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

August 8, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT, ABVX, CYTK, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

$94.13 -4.16 (-4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$95.08 +0.95 (+1.00%)

As of 07:45 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Cytokinetics NASDAQ:CYTK

$65.81 -1.78 (-2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$65.68 -0.13 (-0.20%)

As of 07:30 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$30.72 +0.53 (+1.76%)

As of 04:00 PM Eastern

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Praxis Precision Medicines NASDAQ:PRAX

$282.12 -18.53 (-6.16%)

Closing price 04:00 PM Eastern

Extended Trading

$282.50 +0.38 (+0.13%)

As of 07:57 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LKFT, ABVX, CYTK, and PRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LKFT, ABVX, CYTK, and PRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LKFT, ABVX, CYTK, and PRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT, ABVX, CYTK, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

Cytokinetics NASDAQ:CYTK

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LKFT, ABVX, CYTK, and PRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LKFT, ABVX, CYTK, and PRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LKFT, ABVX, CYTK, and PRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT, ABVX, CYTK, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

Cytokinetics NASDAQ:CYTK

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools